聚乙二醇干扰素治疗期间，血清HBV RNA与肝内cccDNA的相关性比

StephenW

Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment

    Xiaomei Wang, Xiumei Chi, Ruihong Wu, Hongqin Xu, Xiuzhu Gao, Lei Yu, Longgen Liu, Mingxiang Zhang, Youwen Tan, Junqi Niu & Qinglong Jin

Virology Journal volume 18, Article number: 4 (2021) Cite this article

    Metrics details

Abstract
Background

Serum hepatitis B virus RNA (HBV RNA) has been reported to be a surrogate marker of intrahepatic cccDNA during nucleos(t)ide analogs therapy. However, in HBeAg-positive patients treated with peg-interferon (peg-IFN), whether HBV RNA is superior to other HBV markers in reflecting cccDNA profile is still unclear.
Methods

Serum HBV RNA, HBcrAg, HBV DNA, and HBsAg were longitudinally assessed among 30 HBeAg-positive patients during 48-week peg-IFN treatment. Besides, intrahepatic cccDNA was detected at baseline and week 48 respectively. Then, the individual correlations between HBV RNA, HBcrAg, HBV DNA, HBsAg, and cccDNA were statistically analyzed.
Results

HBV RNA levels decreased more rapidly in patients with HBeAg seroconversion than those without HBeAg seroconversion. Among all patients, cccDNA correlated better with HBV RNA than with HBcrAg, HBV DNA, and HBsAg at baseline. After 48 weeks peg-IFN treatment, cccDNA still correlated more strongly with HBV RNA than other HBV markers. Further analysis indicated that in patients with HBeAg seroconversion cccDNA strongly correlated with HBV RNA and HBcrAg, whereas not correlate with HBV DNA and HBsAg. While in patients without HBeAg seroconversion, cccDNA highly correlated with HBV RNA and HBV DNA, moderately correlated with HBcrAg, and not correlated with HBsAg.
Conclusion

Compared to HBcrAg, HBV DNA, and HBsAg, serum HBV RNA correlated more strongly with intrahepatic cccDNA levels before and after 48-week peg-IFN treatment. The level of serum HBV RNA may be a superior surrogate marker in reflecting the intrahepatic cccDNA profile in HBeAg-positive patients during peg-IFN treatment.

Trial registration ClinicalTrials, NCT03546530. Registered 1 January 2015. https://clinicaltrials.gov/ct2/r ... p;term=NCT03546530.

StephenW

聚乙二醇干扰素治疗期间，血清HBV RNA与肝内cccDNA的相关性比其他HBV标记更强

    王晓梅，迟秀梅，吴瑞红，徐宏琴，高秀竹，余雷，刘龙根，张明祥，谭友文，牛俊奇和金庆龙

病毒学杂志第18卷，文章编号：4（2021）引用本文

    指标详细信息

抽象
背景

据报道，在核苷酸类似物治疗期间，血清乙型肝炎病毒RNA（HBV RNA）是肝内cccDNA的替代标志物。然而，在接受聚乙二醇干扰素（peg-IFN）治疗的HBeAg阳性患者中，HBV RNA在反映cccDNA谱方面是否优于其他HBV标记尚不清楚。
方法

在48周的聚乙二醇干扰素治疗期间，对30名HBeAg阳性患者的血清HBV RNA，HBcrAg，HBV DNA和HBsAg进行了纵向评估。此外，分别在基线和第48周检测到肝内cccDNA。然后，对HBV RNA，HBcrAg，HBV DNA，HBsAg和cccDNA之间的个体相关性进行统计分析。
结果

HBeAg血清转化患者的HBV RNA水平下降速度要快于HBeAg血清转化患者。在所有患者中，基线时cccDNA与HBV RNA的相关性高于与HBcrAg，HBV DNA和HBsAg的相关性。经过peg-IFN治疗48周后，与其他HBV标记相比，cccDNA与HBV RNA的相关性仍然更高。进一步的分析表明，在HBeAg血清转化患者中，cccDNA与HBV RNA和HBcrAg密切相关，而与HBV DNA和HBsAg不相关。在没有HBeAg血清转换的患者中，cccDNA与HBV RNA和HBV DNA高度相关，与HBcrAg中等相关，而与HBsAg不相关。
结论

与HBcrAg，HBV DNA和HBsAg相比，peg-IFN治疗48周之前和之后，血清HBV RNA与肝内cccDNA水平的相关性更强。血清HBV RNA水平可能是反映peg-IFN治疗期间HBeAg阳性患者肝内cccDNA谱的优良替代指标。

试验注册ClinicalTrials，NCT03546530。 2015年1月1日注册。https://clinicaltrials.gov/ct2/results?cond=&term=NCT03546530。

StephenW

https://virologyj.biomedcentral. ... /s12985-020-01471-2